FGFR Inhibitor ET0111 Monotherapy in Patients With Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2025-05-01
Target enrollment:
Participant gender:
Summary
This is a Phase I, open-label, multi-center, dose-finding study to assess the safety,
pharmacokinetics, and preliminary efficacy of ET0111 in patients with advanced solid tumors.
It is anticipated that approximately 37 subjects will be enrolled in the dose-escalation
phase of the study. ET0111 will be administered orally once daily (QD) in 21-day treatment
cycles.